Editorial
Editorial board, sourcing & review policy
How this site is researched, written and reviewed — and how we keep ourselves accountable.
Editorial board
Editorial Direction
Metabolic Peptides Editorial Team
Cross-disciplinary UK research writers
Coordinates the site's review schedule, source vetting and UK regulatory framing. Specialises in translating Phase 2/3 incretin and growth-hormone-axis trial data into neutral, research-only summaries for a UK audience.
- Selecting which compounds the site covers based on published evidence depth and UK research interest
- Setting the review cadence and re-checking MHRA / EMA status changes
- Verifying all trial citations against the original publication or registry record
Independent scientific review
Scientific Review Panel
Postgraduate biomedical and pharmacology contributors
Independent reviewers cross-check every peptide profile against the most recent peer-reviewed trial publications, regulatory bulletins (MHRA Drug Safety Updates, EMA EPARs) and the manufacturer's investigator brochures where publicly available. Reviewers carry no commercial relationship with any manufacturer or supplier mentioned on this site.
- Pharmacology fact-check on every mechanism-of-action section
- Safety profile verification against the latest published trial data
- UK regulatory status confirmation prior to publication and at each review cycle
Regulatory & compliance
UK Regulatory Desk
MHRA / EMA / FDA compliance research
Tracks MHRA licensing changes, EMA EPAR updates, FDA labelling decisions and Yellow Card Scheme pharmacovigilance signals. Ensures every page distinguishes accurately between MHRA-licensed prescription medicines (tirzepatide, semaglutide, liraglutide) and research peptides supplied for laboratory and analytical use only.
- Monitoring MHRA Drug Safety Updates for status changes
- Re-verifying licensing status on each peptide profile at every review cycle
- Maintaining accurate UK-specific brand-name mapping (Mounjaro, Wegovy, Ozempic, Saxenda, Rybelsus, Zepbound)
Editorial policy
Sourcing standard
Every claim is sourced to a peer-reviewed publication, regulatory document, or manufacturer's investigator brochure. Trial names are cited explicitly (SURMOUNT, SURPASS, STEP, SUSTAIN, SELECT, SCALE, LEAD, TRIUMPH) so back-traceable.
Review frequency
Pages are reviewed on a periodic cadence and whenever the underlying evidence or UK regulatory status materially changes. The "Last fact-checked" / "Last reviewed" date on each page reflects the most recent review.
Conflicts of interest
The editorial team has no commercial relationship with any manufacturer of incretin medicines (Eli Lilly, Novo Nordisk, Pfizer, Boehringer Ingelheim, Amgen, Zealand, Hanmi, Theratechnologies, etc.), with any compounding pharmacy, or with any online pharmacy or telehealth service. The site does accept a sponsored advertising partnership from PeptideBarn.co.uk — a UK research-peptide reference supplier. Sponsored placements appear in clearly labelled ad units (hero banner, sidebar cards, brand-page CTA, footer partner column) with rel="sponsored" outbound links per Google Webmaster guidelines; the label "Sponsored" appears before the ad content per UK ASA / CAP Code disclosure requirements. Editorial content is independent of sponsorship: trial coverage, molecule profiles, safety-signal tracking and regulatory framing are selected by editorial standards alone. We also cross-link to a sister editorial resource, PeptideAuthority.co.uk. We do not sell, ship, prescribe or compound peptides.
Corrections policy
Evidence-backed correction requests are reviewed within five working days. Corrections are noted with a dated changelog entry on the affected page.
Medical disclaimer (summary)
All content is for laboratory and research use only. Nothing on this site constitutes medical advice. Consult a qualified UK healthcare professional before any decision affecting your health.
Full text: Research-use disclaimer.